All In Biotech

Drug Trial Radar · NCT04681131

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

85

Actual

Start

Mar 17, 2021

Primary completion

Jul 9, 2025

Study completion Jul 9, 2025

Sponsor

Lead sponsor
BioAtla, Inc.Industry
Sponsor type
Industry
First posted
Dec 23, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC

Conditions

  • Non-Small-Cell Lung Cancer

Interventions

  • CAB-AXL-ADCBiological

    Conditionally active biologic anti-AXL antibody drug conjugate

  • PD-1 inhibitorBiological

    PD-1 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Objective Response Rate (ORR) per RECIST v1.1Time frame: Up to 24 months
  2. Incidence of Adverse Events (AEs)or Serious Adverse Events (SAEs) as assessed by CTCAE v4.03/v5Time frame: Up to 24 months

Locations

60 sites in 7 countries. Site status is shown where the registry gives one.

  • City of Hope - Duarte

    Duarte, California

  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center

    Irvine, California

  • California Research Institute

    Los Angeles, California

  • USC Norris

    Los Angeles, California

  • Cedars-Sinai

    Los Angeles, California

  • University of California, San Diego (UCSD) - Moores Cancer Center

    San Diego, California

  • American Institute of Research

    Whittier, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Florida Cancer Specialists & Research Institute

    Fleming Island, Florida

  • Florida Cancer Specialists & Research Institute

    Fort Myers, Florida

  • Florida Cancer Specialist

    St. Petersburg, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Augusta University - Georgia Cancer Center

    Augusta, Georgia

  • Baptist Health Systems

    Lexington, Kentucky

  • University of Kentucky

    Lexington, Kentucky

  • Norton Cancer Institute, Brownsboro Hospital Campus

    Louisville, Kentucky

  • Hematology/Oncology Clinic

    Baton Rouge, Louisiana

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada

    Henderson, Nevada

  • OptumCare Cancer Care

    Las Vegas, Nevada

  • Roswell Park

    Buffalo, New York

  • NYU Langone Health

    New York, New York

  • FirstHealth Outpatient Cancer Center

    Pinehurst, North Carolina

  • Gabrail Cancer Research Center

    Canton, Ohio

  • The Lindner Research Center at the Christ Hospital

    Cincinnati, Ohio

  • UPMC Cancer Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina- Hollings Cancer Center

    Charleston, South Carolina

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Mary Crowley Cancer Research

    Dallas, Texas

  • MD Anderson

    Houston, Texas

  • Henry Dunant Hospital Center

    Athens, Greece

  • Metropolitan Hospital Perseus Healthcare Group SA

    Piraeus, Greece

  • Bioclinic Thessaloniki

    Thessaloniki, Greece

  • European Interbalkan Medical Center

    Thessaloniki, Greece

  • ICON Cancer Centre

    Hong Kong, Hong Kong

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Hong Kong United Oncology Centre

    Kowloon, Hong Kong

  • Hospital San Giuseppe Moscati

    Avellino, Italy

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.